Imbio

Imbio is a medical imaging software company based in Minneapolis, founded in 2012. The company specializes in fully automated 3D visualization and quantitative analysis solutions for lung and cardiothoracic imaging diagnostics. Imbio develops AI-powered technologies that convert standard medical images, such as CT scans, into detailed visual maps and quantitative reports. These outputs help physicians gain personalized insights to enhance diagnosis, treatment planning, and patient monitoring, particularly for lung diseases like COPD and lung cancer. Imbio offers several FDA-cleared solutions, including Lung Density Analysis for detecting emphysema and COPD, Lung Texture Analysis for identifying interstitial lung abnormalities, and RV/LV Analysis for measuring right ventricular dilation. Their SeleCT Analysis tool, developed with Olympus Medical, assesses emphysema severity to qualify patients for specific treatments. Imbio's software integrates into existing radiology workflows, supporting healthcare providers like radiologists and pulmonologists in delivering faster and more accurate diagnoses. The company aims to bridge the gap between quantitative imaging and modern healthcare demands, fostering a culture of innovation and collaboration.

• Employees 8
• Founded 2012
• Annual Revenue $7000000
• Total Funding $2577695